XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Q1 2026 | 0.52 | 0.60 | +15.38% | $177.4M | ✅ Beat | +0.04% | -7.26% | -8.91% |
| 2026-02-26 | Q4 2025 | 0.78 | 0.57 | -26.92% | $196.9M | ❌ Miss | -5.58% | +1.20% | +1.28% |
| 2025-11-06 |
| Q3 2025 |
| 0.56 |
| 0.70 |
| +25.00% |
| $179.5M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | 0.62 | 0.74 | +19.35% | $181.1M | ✅ Beat | -3.28% | +10.07% | +18.59% |
| 2025-02-27 | Q4 2024 | 0.83 | 0.91 | +9.64% | $187.3M | ✅ Beat | -5.24% | -5.99% | -2.09% |
| 2024-11-06 | Q3 2024 | 0.70 | 0.79 | +12.86% | $168.6M | ✅ Beat | +0.17% | -6.90% | +9.05% |
| 2024-07-30 | Q2 2024 | 0.70 | 0.89 | +27.14% | $178.0M | ✅ Beat | +5.68% | +10.59% | -21.39% |
| 2024-05-07 | Q1 2024 | 0.62 | 0.62 | +0.00% | $167.1M | ➖ Inline | +11.84% | +16.26% | +9.85% |
Showing last 8 quarters.